PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION
CALDERWOOD & HARKNESS LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103
MATTER STATUS REPORT Fourth Quarter 2022 (October 1 – December 31, 2022)
January 5, 2023
Matter: Penterra Pharmaceuticals Corp. — IRS Transfer Pricing Examination Defense
Matter Number: 1018-00009
Prepared by: Leonard Cross, Responsible Partner; Sylvia Hartwell, Billing Partner
Distributed to:
Marcus Whitfield, Vice President — Global Tax, Penterra Pharmaceuticals Corp. Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp. Rajesh Iyer, Chief Financial Officer, Penterra Pharmaceuticals Corp.
Copies:
Garrett Simmons, Lead Associate, Calderwood & Harkness LLP Leila Nazari, Working Associate, Calderwood & Harkness LLP
This memorandum is a privileged and confidential attorney-client communication prepared by Calderwood & Harkness LLP for the exclusive use of the addressees identified above. This document constitutes attorney work product protected under Federal Rule of Civil Procedure 26(b)(3) and the common-law attorney-client privilege. It may not be disclosed, distributed, or otherwise disseminated to any person not identified above without the prior written consent of Calderwood & Harkness LLP. Receipt by any unintended recipient does not constitute a waiver of any applicable privilege.
Right-click to update Table of Contents
1. Executive Summary
This Matter Status Report summarizes the activities undertaken by Calderwood & Harkness LLP ("C&H") during the fourth quarter of 2022 (October 1 through December 31, 2022) in defense of Penterra Pharmaceuticals Corp. ("PPC," EIN 22-3741856) against the ongoing IRS Large Business & International Division ("LB&I") transfer pricing examination (Exam Team Identifier LB&I-NE-TP-2022-00641) for Tax Years 2017 through 2020.
The examination was formally opened on May 16, 2022, and we are now approximately seven months into the Information Document Request ("IDR") phase of the examination. We are pleased to report that significant progress was achieved during Q4 2022 across all major defense workstreams. The key accomplishments and developments during the quarter are summarized below.
IDR Activity. During Q4 2022, C&H responded to IDRs Nos. 10 through approximately 12, as well as several additional IDRs in the mid-teens range (including IDR No. 15), producing substantial documentation concerning intercompany agreements, product revenue data, the physical presence and office lease of Penterra Biologics Ireland Limited ("PBI"), and regulatory expenditures incurred by PBI across non-Americas territories. In total, the IRS has issued approximately 17 to 18 IDRs to date out of what we anticipate will ultimately be 47 total IDRs spanning the period from June 2022 through approximately September 2023. A running master document production index with Bates numbering is maintained by C&H, and a privilege log has been updated with each IDR response.
Functional Analysis. The initial tranche of the comprehensive functional analysis of PBI's operations for the 2017–2020 period was completed in October 2022. This analysis, prepared by C&H in coordination with Whitmore Valuation Group ("WVG"), documents PBI's substantial functions, assets, and risks — including regulatory affairs, commercial strategy, supply-chain management, and medical affairs activities conducted from PBI's Dublin offices. The functional analysis is a cornerstone of PPC's defense against any IRS challenge to PBI's economic substance and DEMPE (Development, Enhancement, Maintenance, Protection, and Exploitation) functions.
Economic Analyses. WVG, engaged under a Kovel arrangement (reference 1018-00009-KV), delivered key economic analyses during Q4 2022 in both draft and final form. Dr. Helena Vasquez and Dr. Rohan Chakrabarti completed and delivered the following: (i) a final Comparable Uncontrolled Transaction ("CUT") analysis of the legacy IP royalty rate; (ii) a final Comparable Profits Method / Transactional Net Margin Method ("CPM/TNMM") analysis of PBI's operating margins; (iii) a final Platform Contribution Transaction ("PCT") valuation analysis using the income method / Discounted cash flow approach; and (iv) a technical memorandum supporting C&H's position on the appropriate weighted average cost of capital ("WACC") discount rate. These analyses collectively confirm the arm's-length character of PPC's intercompany arrangements and provide a robust foundation for defending PPC's transfer pricing positions.
Irish Coordination. Leila Nazari continues to coordinate with Ciarán Thornbury at Thornbury & Keogh ("T&K"), PPC's Irish counsel, regarding PBI substance documentation, Irish Revenue filings, and Knowledge Development box documentation.
Examination Phase. No Notice of Proposed Adjustment ("NOPA") has been issued, and the examination remains squarely in the information-gathering phase. While IRS economist Dr. Alan Washburne has been identified as assigned to the case, he has not yet engaged directly with C&H during Q4 2022. The IRS examining team has indicated that economist involvement is forthcoming, and we anticipate increasing engagement from Dr. Washburne in Q1 2023. No direct contact from IRS Office of Chief Counsel attorneys has been received during the quarter.
Overall Assessment. The examination is proceeding as anticipated. There have been no unexpected developments. PPC's transfer pricing positions remain well-supported by contemporaneous documentation, the completed functional analysis, and the economic analyses delivered by WVG. C&H's defense strategy remains on track, and we continue to build the factual and analytical record necessary to address the anticipated IRS positions effectively.
2. Examination Status and IRS Activity
2.1 Examining Team and Key IRS Personnel
The IRS LB&I examining team assigned to PPC's transfer pricing examination consists of the following key personnel:
Lead Revenue Agent Patricia Dunleavy remains the primary point of contact for all IDR-related communications. C&H's interactions with Ms. Dunleavy during Q4 2022 have been professional and have followed the established IDR response protocols. All IDR responses are submitted to Ms. Dunleavy via the IRS's secure electronic submission portal, with copies provided to Supervisory Revenue Agent Meskill.
As noted above, IRS economist Dr. Alan Washburne has been identified as assigned to PPC's examination. The IRS examining team indicated during a telephone conference in mid-November 2022 that Dr. Washburne would be involved in reviewing PPC's transfer pricing economics, though he has not yet initiated direct engagement with C&H or WVG. We anticipate that Dr. Washburne will become more actively involved in Q1 2023, particularly as the IRS team begins its substantive review of PPC's cost-sharing arrangements and the legacy IP royalty rate. C&H and WVG are prepared to engage with Dr. Washburne as appropriate.
IRS Office of Chief Counsel Attorney-Advisor Franklin Rosario has been identified as the designated counsel for the examination. No direct communication has been received from Mr. Rosario during Q4 2022 or at any point since the examination was opened. The absence of direct Chief Counsel engagement at this stage is not unusual and is consistent with the information-gathering phase of the examination.
It is noted that PPC was not in the IRS Compliance Assurance Process ("CAP") for the tax years at issue (2017–2020). Accordingly, there are no pre-filing agreements or CAP-related resolutions applicable to any of the transfer pricing positions under examination.
2.2 IDR Activity During Q4 2022
C&H continued to respond to IDRs on behalf of PPC throughout Q4 2022. The following IDRs were responded to or addressed during the quarter:
IDR No. 10 — Response Date: September 20, 2022 (carryover from Q3 2022). This IDR requested PBI's contract manufacturing agreement with Penterra Manufacturing Ireland Ltd. ("PMI"). C&H produced the PBI-PMI contract manufacturing agreement, which provides for a cost-plus-8% markup on manufacturing services provided by PMI to PBI. The response included the complete executed agreement, all amendments, and supporting documentation evidencing the markup calculation for each of the tax years at issue. While the formal response was submitted during Q3, follow-up correspondence and supplemental production were completed in early October 2022.
IDR No. 11 — Response Date: October 3, 2022. This IDR requested product revenue data by territory for PPC's three principal pharmaceutical products — Veritaxol, Imvara, and Cerulon — for each of the tax years 2017 through 2020. C&H compiled and produced the requested data in tabular format, broken down by Americas and non-Americas territories. The key revenue figures produced for Tax Year 2020 were as follows:
Corresponding data for Tax Years 2017, 2018, and 2019 was also produced. The production included underlying sales reports, invoices to third-party distributors, and reconciliation schedules to PPC's consolidated financial statements. This data is relevant to the IRS's analysis of cost-sharing ratios, reasonably anticipated benefit calculations, and the allocation of residual profits between PPC and PBI.
IDR No. 12 — Response Date: October 12, 2022. This IDR requested documentation evidencing PBI's physical office presence in Ireland, including office lease agreements, floor plans, and utility records. C&H produced PBI's office lease for approximately 18,000 square feet of office space at Sandyford Business Park, Dublin D18 K7T4. The production included the executed lease agreement, renewal correspondence, floor plans, building access records, and photographic documentation of PBI's offices. This evidence is directly relevant to PBI's economic substance and is expected to be a focal point of any IRS challenge to PBI's substantive presence in Ireland.
IDR No. 14 — Extension Granted. IDR No. 14 requested detailed documentation of intercompany service fees paid between PPC and PBI during the 2017–2020 period. Given the volume and complexity of the documentation involved, Leonard Cross submitted a letter to Lead Revenue Agent Dunleavy dated September 20, 2022, requesting a 30-day extension of the response deadline. The extension was granted by Ms. Dunleavy. The response to IDR No. 14 was being prepared during Q4 2022 and is expected to be finalized in early Q1 2023.
IDR No. 15 — Response Date: November 8, 2022. This IDR requested documentation of PBI's regulatory expenditures and submissions across non-Americas territories for the 2017–2020 period. C&H produced comprehensive documentation evidencing PBI's cumulative regulatory expenditures of €47.2 million across 68 country markets during the four-year examination period. The production included regulatory submission logs, country-by-country regulatory filing records, external regulatory consultant invoices, and internal cost allocation schedules. This data is critical to demonstrating PBI's substantive functions in the area of regulatory affairs, a key component of the DEMPE analysis.
IDRs Nos. 13, 16, and 17 — These IDRs were received during Q4 2022 and were either partially responded to during the quarter or are in the process of being prepared for response in early Q1 2023. IDR No. 13 relates to PBI's headcount and organizational structure; IDR No. 16 concerns PBI's marketing expenditures and commercial activities; and IDR No. 17 requests details of PBI's treasury and cash management operations. Nazari and Simmons are coordinating the responses to these IDRs in consultation with PPC's internal tax and finance teams.
Running Totals. As of December 31, 2022, the IRS has issued approximately 17 to 18 IDRs in total. Based on the pace and scope of the examination, C&H anticipates that the IRS will ultimately issue approximately 47 total IDRs, with the IDR phase continuing through approximately September 2023. C&H maintains a master document production index that tracks all documents produced by Bates number, IDR reference, date of production, and description of documents. The privilege log is updated concurrently with each IDR response and reflects all documents withheld on attorney-client privilege or work-product grounds.
2.3 IRS Focus Areas Observed
Based on the pattern and content of the IDRs received to date, C&H has identified three primary areas of IRS focus:
(1) CSA Cost-Sharing Ratios and Reasonably Anticipated Benefit ("RAB") Calculations. The IRS team has requested detailed breakdowns of R&D cost pools, revenue data by territory, and the methodology underlying PBI's cost-sharing percentages. The nature and depth of these requests suggest that the IRS is scrutinizing PBI's cost-sharing ratios and may challenge the RAB calculations that underpin those ratios. This is the area with the largest potential exposure.
(2) Legacy IP Royalty Rate of 4.5%. Multiple IDRs have focused on the terms of the legacy IP license agreement, the comparable license agreements used to establish the 4.5% royalty rate, and the financial performance of the legacy compounds. The IRS appears to be building a record to support a challenge to the arm's-length nature of the 4.5% rate, potentially arguing for a significantly higher rate.
(3) PBI's Economic Substance and DEMPE Functions. IDR requests during Q4 2022 — particularly IDRs Nos. 12, 13, and 15 — suggest an increasing IRS focus on PBI's substantive presence in Ireland and independent decision-making capacity. The IRS appears to be gathering evidence to evaluate whether PBI exercises genuine control over the development, enhancement, maintenance, protection, and exploitation of the intellectual property attributed to it under the CSA and legacy license arrangements.
Leonard Cross communicated strategic observations to Sylvia Hartwell in October 2022 regarding the IRS's apparent focus on the royalty rate and PBI substance. Cross noted that the pattern of IDR requests is consistent with C&H's initial assessment of the likely areas of IRS challenge, and that the defense strategy as outlined in C&H's June 2022 engagement memorandum remains on track. No adjustments to the overall defense strategy are recommended at this time.
3. Defense Workstream Updates
3.1 Functional Analysis
The comprehensive functional analysis of PBI for the 2017–2020 period was completed in initial form in October 2022. This analysis was prepared by C&H in close coordination with WVG and represents a foundational element of PPC's defense against anticipated IRS challenges to PBI's economic substance and DEMPE functions.
The functional analysis documents PBI's functions, assets, and risks across four primary operational domains: regulatory affairs, commercial strategy, supply-chain management, and medical affairs. The analysis draws on documentary evidence, employee interview data, and financial records to establish that PBI is a substantive operating entity exercising independent decision-making authority over the exploitation of pharmaceutical intellectual property in non-Americas markets.
The key evidence compiled and documented in the functional analysis includes the following:
• Headcount Growth: PBI employed 185 individuals as of year-end 2020, up from 52 employees at the time of PBI's establishment in 2012. This growth trajectory demonstrates PBI's expanding operational scope and its increasing capacity to perform substantive functions independently.
• Board Activity: A total of 42 PBI board meetings were held in Dublin during the 2017–2020 period, consisting of quarterly regular meetings and special sessions. These board meetings were conducted in person in Dublin (with limited telephonic participation by U.S.-based directors for certain special sessions) and involved substantive decision-making on pricing, market entry, regulatory strategy, and capital expenditures.
• Regulatory Expenditures: PBI incurred cumulative regulatory expenditures of €47.2 million on non-Americas regulatory submissions during 2017–2020, covering submissions across 68 country markets. PBI's regulatory affairs team, based in Dublin, was responsible for preparing, submitting, and managing these regulatory filings.
• Independent Pricing Decisions: PBI independently set prices for Veritaxol, Imvara, and Cerulon across 68 country markets, taking into account local market conditions, reimbursement frameworks, competitive dynamics, and regulatory requirements. Pricing decisions were approved by PBI's Managing Director and, for significant pricing changes, by PBI's board of directors.
• Managing Director Leadership: Aidan Naughton, PBI's Managing Director, has been based in Dublin throughout the examination period and leads PBI's independent commercial operations. Mr. Naughton reports to PBI's board of directors and exercises substantial decision-making authority over PBI's day-to-day operations.
Personnel Interviews. During August and September 2022, Garrett Simmons and Leila Nazari traveled to Dublin and conducted interviews of 12 key PBI employees, including the Managing Director, heads of regulatory affairs, commercial strategy, medical affairs, and supply-chain management, as well as senior finance personnel. The interviews were designed to document the nature, scope, and independence of each employee's functions and to confirm that key decisions affecting PBI's operations are made in Dublin by PBI personnel rather than by PPC personnel in the United States. Interview summaries for all 12 interviews have been completed and are on file as attorney work product.
Board Minutes Analysis. Leila Nazari completed a comprehensive memorandum cataloguing all 42 PBI board meetings held during the 2017–2020 period. The memorandum documents the key decisions made at each meeting, organized by subject matter, including pricing decisions, market entry and withdrawal decisions, regulatory submission approvals, capital expenditure authorizations, and personnel decisions. This memorandum demonstrates that PBI's board was actively and substantively engaged in governing PBI's operations and that key strategic decisions were made in Dublin.
This functional analysis work directly supports PPC's rebuttal of the IRS's anticipated economic substance challenge and DEMPE arguments. The evidence assembled demonstrates that PBI performs significant functions, uses substantial assets, and assumes meaningful risks with respect to the development, enhancement, maintenance, protection, and exploitation of the intellectual property in non-Americas territories.
3.2 Whitmore Valuation Group Economic Analyses
WVG, engaged under a Kovel arrangement (reference 1018-00009-KV), delivered four principal economic analyses during Q4 2022. These analyses were prepared by Dr. Helena Vasquez (Lead Economist) and Dr. Rohan Chakrabarti (Supporting Economist) and are summarized below.
CUT Analysis — Legacy IP Royalty Rate (Final Report, November 2022). WVG completed its final CUT analysis of PPC's legacy IP royalty rate of 4.5%. The analysis identified 14 comparable uncontrolled pharmaceutical license agreements through a systematic search of publicly available licensing databases, SEC filings, and industry publications. The 14 comparables were screened based on comparability factors including the nature of the licensed intellectual property (pharmaceutical compound IP), the scope of territorial rights, the stage of development, and the term of the license. The interquartile range of royalty rates observed in the 14 comparable agreements was 3.1% to 6.8%, with a median of 4.4%. PPC's legacy IP royalty rate of 4.5% falls squarely within the arm's-length range and is virtually identical to the median. This analysis directly rebuts any IRS attempt to increase the royalty rate. Based on the pattern of IDR requests and prior IRS examination activity in comparable cases, C&H anticipates that the IRS may propose a royalty rate as high as 11.0%, based on its own selection of purportedly comparable agreements. The WVG CUT analysis provides a strong foundation for demonstrating that the IRS's anticipated position would be inconsistent with the arm's-length standard.
CPM / TNMM Analysis — PBI Operating Margins (Final Report, November 2022). WVG completed its final CPM/TNMM analysis of PBI's operating margins. The analysis tested PBI's operating margins for each of the four tax years at issue against a set of 22 comparable distributors and IP-holding companies identified through a systematic benchmarking search. The comparable companies were screened based on functional comparability, industry, geographic scope, and financial data availability. PBI's operating margins fell within the interquartile range of the 22 comparables in all four years (2017–2020), confirming that PBI's reported operating results are consistent with arm's-length outcomes. This analysis serves as a corroborative check on the CUT analysis and provides an independent basis for demonstrating the arm's-length nature of PPC's intercompany arrangements.
PCT Valuation Analysis — Income Method / DCF (Final Report, December 2022). WVG completed its final PCT valuation analysis, which re-valued the platform contribution transaction entered into by PBI on July 1, 2012, using the income method / Discounted cash flow approach. The analysis utilized updated revenue projections and applied a WACC of 9.8%, which represents C&H's and WVG's position on the appropriate discount rate for a pharmaceutical IP asset of this risk profile. The analysis concluded that the $312 million PCT payment made by PBI on July 1, 2012 falls within the arm's-length range of $278 million to $361 million. C&H anticipates that the IRS may seek to apply a lower WACC — potentially as low as 7.2% — which would result in a substantially higher PCT valuation. While the PCT itself occurred in 2012 and is outside the formal examination years, the IRS may seek to use an alleged undervaluation of the PCT as a basis for recharacterizing the ongoing CSA and royalty arrangements during the 2017–2020 period. The WVG PCT analysis is designed to preemptively address this anticipated IRS position.
WACC / Discount Rate Analysis (Technical Memorandum, December 2022). Dr. Vasquez prepared a technical memorandum supporting the 9.8% WACC utilized in the PCT valuation analysis. The memorandum provides a detailed analysis of risk premiums, beta comparables drawn from publicly traded pharmaceutical and biotechnology companies, and pharmaceutical-industry cost of capital data. The memorandum also critiques the application of a lower 7.2% discount rate, demonstrating that such a rate would fail to account for the specific risk characteristics of PBI's pharmaceutical IP portfolio, including pipeline risk, regulatory risk, and commercial risk in non-Americas markets. The technical memorandum is intended to serve as the analytical foundation for any engagement with IRS economist Dr. Washburne on discount rate issues.
Benchmarking Study Workbook. WVG has finalized a comprehensive benchmarking study workbook (in Excel format) containing all search criteria, screening results, financial data, and comparability analyses for both the 14 CUT comparable agreements and the 22 CPM/TNMM comparable companies. This workbook serves as the detailed supporting documentation for the CUT and CPM/TNMM analyses and is maintained under the Kovel arrangement.
All WVG work product has been prepared under the Kovel arrangement established at the outset of the engagement, and privilege has been maintained over all communications, draft reports, and final reports. WVG personnel have been instructed to direct all communications regarding the examination exclusively through C&H.
3.3 Legal Research and Analysis
C&H's associate team has completed a comprehensive library of research memoranda addressing the legal and regulatory framework governing PPC's transfer pricing positions. The following memoranda were completed during Q3 2022 or earlier and remain current as of Q4 2022:
1. IRC § 482 Arm's-Length Standard and Best Method Rule Analysis — Nazari and Simmons, July 20, 2022. This memorandum analyzes the general framework for IRS transfer pricing adjustments under IRC § 482, including the arm's-length standard, the best method rule, and the selection of the most reliable transfer pricing method for each category of intercompany transaction at issue.
2. QCSA Regulatory Analysis under Treas. Reg. § 1.482-7 — Nazari, August 5, 2022. This memorandum analyzes the regulatory requirements for qualified cost-sharing arrangements, including the cost-sharing percentage methodology, reasonably anticipated benefit calculations, and the PCT requirements applicable to PBI's CSA entered into on July 1, 2012.
3. Arm's-Length Royalty Rate under Treas. Reg. § 1.482-4 — Simmons, August 12, 2022. This memorandum analyzes the regulatory framework for evaluating the arm's-length character of royalty rates on intangible property, including the CUT method and the comparable adjustable transaction method.
4. Economic Substance Doctrine and DEMPE Functions Analysis — Nazari, August 18, 2022. This memorandum analyzes the economic substance doctrine as applied to transfer pricing arrangements, the OECD's DEMPE framework as adopted in the 2017 revisions to the Transfer Pricing Guidelines, and the relevance of DEMPE analysis to the IRS's anticipated challenges to PBI's functions and substance.
5. IRC § 6662(e) Penalty Protection and Reasonable Cause Defense — Simmons, September 2, 2022. This memorandum analyzes the substantial valuation misstatement penalty provisions of IRC § 6662(e), the contemporaneous documentation requirements for transfer pricing penalty protection, and the reasonable cause defense available to PPC.
6. TCJA Impact on Transfer Pricing Positions — TY 2017 at 35% vs. TY 2018–2020 at 21% — Nazari, August 25, 2022. This memorandum analyzes the impact of the Tax Cuts and Jobs Act of 2017 on PPC's transfer pricing positions, including the reduction in the U.S. corporate tax rate from 35% to 21% and the implications for the magnitude of any IRS transfer pricing adjustment.
7. Altera and Harborview Corporation Case Law Analysis — Simmons and Nazari, September 15, 2022. This memorandum analyzes the holdings and implications of Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019), and Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018), for PPC's transfer pricing positions, including the treatment of stock-based compensation in cost-sharing arrangements and the selection of the best method for pricing intercompany IP transactions.
8. IRC § 367(d) Outbound IP Transfer Analysis — Nazari, September 28, 2022. This memorandum analyzes the potential application of IRC § 367(d) to PPC's 2012 transfer of intellectual property rights to PBI, including the interaction between § 367(d) and the CSA regulations.
9. OECD Transfer Pricing Guidelines (2017 & 2022 Revisions) as Persuasive Authority — Simmons, October 10, 2022. This memorandum analyzes the role of the OECD Transfer Pricing Guidelines as persuasive (but not binding) authority in IRS transfer pricing examinations and litigation, with particular attention to the 2017 revisions incorporating DEMPE analysis and the 2022 revisions addressing financial transactions.
10. IRS IDR Enforcement Procedures Research — Nazari, August 2022. This memorandum addresses the IRS's IDR enforcement process, including the escalation procedures set forth in the IRS's Internal Revenue Manual for IDR non-compliance, and the rights and obligations of taxpayers in responding to IDRs.
The following additional research memorandum was completed during Q4 2022:
11. GILTI and BEAT Impact Analysis on PPC's Transfer Pricing Positions for TY 2018–2020 — Nazari, October 2022. This memorandum analyzes the interaction between PPC's transfer pricing positions and the Global Intangible Low-Taxed Income ("GILTI") provisions of IRC § 951A and the Base Erosion and Anti-Abuse Tax ("BEAT") provisions of IRC § 59A, both of which became effective for tax years beginning after December 31, 2017. The memorandum assesses whether any IRS transfer pricing adjustment would trigger or increase PPC's exposure to GILTI or BEAT and evaluates the potential offsetting effects.
All research memoranda are privileged attorney work product and are maintained in C&H's secure document management system.
3.4 Intercompany Agreement Analysis
C&H has completed a comprehensive analysis of each of PPC's principal intercompany agreements within the Penterra group:
Cost-Sharing Arrangement. Garrett Simmons completed an analysis of the CSA (effective July 1, 2012) for compliance with the requirements of Treas. Reg. § 1.482-7 in July 2022. The analysis confirmed that the CSA satisfies the regulatory requirements for a qualified cost-sharing arrangement, including the administrative requirements, the use of reasonably anticipated benefits as the basis for cost-sharing ratios, and the proper treatment of the PCT. The analysis also identified potential areas of IRS challenge and assessed the strength of PPC's positions.
Legacy IP License Agreement. Leila Nazari completed an analysis of the legacy IP license agreement between PPC and PBI, under which PBI pays a 4.5% royalty on non-Americas net sales of legacy compounds, under Treas. Reg. § 1.482-4 in July 2022. The analysis confirmed that the 4.5% royalty rate was established on an arm's-length basis using the CUT method and that the terms of the license are consistent with comparable uncontrolled agreements.
PMI Contract Manufacturing Agreement. Nazari completed an analysis of the contract manufacturing agreement between PBI and Penterra Manufacturing Ireland Ltd. ("PMI") in August 2022. The agreement provides for PMI to manufacture pharmaceutical products for PBI on a cost-plus-8% basis. Nazari confirmed that the cost-plus-8% markup is arm's-length under the cost-plus method, based on benchmarking against comparable contract manufacturing arrangements in the pharmaceutical industry.
Intercompany Agreement Matrix. A comprehensive matrix of all intercompany agreements within the PPC group — including the CSA, legacy IP license, PMI manufacturing agreement, and various intercompany service agreements — has been prepared and is maintained in an Excel workbook. The matrix identifies the parties, effective dates, terms, pricing methodology, and arm's-length analysis for each agreement.
PHL Entity Classification Memorandum. Nazari completed a memorandum in July 2022 analyzing the entity classification of Penterra Holdings Luxembourg S.à r.l. ("PHL") for U.S. federal tax purposes. The memorandum concluded that PHL is properly classified as a disregarded entity for U.S. federal tax purposes, with PBI as its regarded owner. This classification is relevant to the characterization of intercompany payments flowing through PHL.
3.5 FIN 48 / ASC 740-10 Reserve Support
Leonard Cross and Garrett Simmons completed a memorandum in September 2022 providing a legal analysis supporting PPC's FIN 48 uncertain tax position reserve of $62.4 million related to PPC's Irish IP structure. The memorandum assessed the uncertain tax position under the two-step framework prescribed by ASC 740-10 (formerly FIN 48): (i) the "more-likely-than-not" recognition threshold, evaluating whether it is more likely than not that PPC's transfer pricing positions will be sustained on examination; and (ii) the measurement step, evaluating the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement.
Based on C&H's analysis of the applicable law, the strength of PPC's transfer pricing positions as supported by contemporaneous documentation and the WVG economic analyses, and the range of potential IRS adjustments, C&H concluded that PPC's $62.4 million FIN 48 reserve is appropriately calibrated.
A letter was sent to Martin Ogilvy at Crestfield & Associates LLP ("Crestfield") on September 20, 2022, providing C&H's legal analysis in support of PPC's FIN 48 reserve. This letter was provided at the request of PPC's audit committee and is intended to support PPC's financial statement disclosures and Crestfield's audit procedures.
The reserve position remains unchanged at $62.4 million as of year-end 2022. No NOPA has been issued by the IRS, and there has been no development during Q4 2022 that would necessitate a revision to the reserve amount. C&H will continue to monitor developments in the examination and advise PPC's tax and finance teams if any change in the reserve is warranted.
3.6 Irish Coordination (Thornbury & Keogh)
Leila Nazari continues to serve as the primary C&H liaison with Ciarán Thornbury at Thornbury & Keogh, PPC's Irish legal counsel (22 Fitzwilliam Square, Dublin 2, Ireland). The coordination with T&K encompasses the following activities:
Irish Revenue Filings. T&K has provided copies of PBI's Irish Revenue filings for the relevant periods, including corporation tax returns, VAT returns, and relevant supplementary filings. These documents have been reviewed by C&H and are maintained in the matter files.
Knowledge Development box Documentation. T&K has provided documentation supporting PBI's claim for the Knowledge Development box ("KDB") relief, which provides for an effective rate of 6.25% on qualifying IP income from FY 2016 forward. The KDB documentation includes PBI's qualifying IP calculations, the identification of qualifying assets, and supporting schedules. This documentation is relevant to PPC's defense because it demonstrates that PBI's IP income is subject to Irish taxation — a factor that underscores PBI's substantive economic activity in Ireland.
PBI Statutory Financial Statements and Tax Returns. PBI's Irish statutory financial statements and tax returns were produced in response to IDR No. 7 on August 25, 2022. The FY 2020 financial statements reflect revenue of €2.14 billion and pre-tax income of €1.06 billion. PBI's income is subject to the Irish standard trading rate of 12.5% (reduced to 6.25% on qualifying KDB income). These financial data are consistent with PBI's status as a substantive operating entity with significant revenue and profitability.
Glenmore Bank Ireland plc Records. T&K has been asked to obtain banking records from Glenmore Bank Ireland plc, PBI's primary Irish banking institution, in anticipation of upcoming IDR responses relating to PBI's treasury operations and cash management activities. Nazari is coordinating with Thornbury on the scope of the records request and the timeline for production.
T&K Fees. T&K's fees to date are nominal, reflecting the relatively limited scope of T&K's involvement during the early phase of the examination. T&K's total estimated engagement fees are projected at €312,500 (approximately $341,200 at current exchange rates).
3.7 Crestfield & Associates Coordination
Garrett Simmons has coordinated with Susan Lam, Transfer Pricing Partner at Crestfield & Associates LLP, on data requests for PPC's contemporaneous transfer pricing documentation for Tax Years 2017 through 2020. Crestfield prepared PPC's original transfer pricing documentation under the penalty-protection standards prescribed by IRC § 6662(e), and this documentation represents the contemporaneous record of PPC's transfer pricing policies and methodologies.
The original contemporaneous transfer pricing documentation for all four tax years at issue was produced in response to IDR No. 4 on August 1, 2022. The production included the master file, local files, and all supporting schedules and analyses for each year.
A follow-up data request was sent by Simmons to Susan Lam on October 18, 2022, seeking detailed breakdowns of PPC's qualified R&D cost pool for each of the four tax years. Crestfield provided the following cost pool data:
This data is essential for the cost-sharing ratio analysis and is being utilized by both C&H and WVG in their respective analyses.
Martin Ogilvy, Engagement Partner at Crestfield, continues in his role as PPC's independent auditor and tax return preparer. Crestfield does not appear as counsel of record in the IRS examination and is not directly engaged with the IRS examining team. All Crestfield interactions with C&H are coordinated to ensure that Crestfield's role as independent auditor is not compromised by the examination defense engagement.
4. Cost-Sharing and Royalty Data Summary
4.1 CSA Cost-Sharing Ratios (PPC Position)
The following table summarizes PBI's cost-sharing percentages and dollar amounts for each of the four tax years at issue, based on PPC's position:
PBI's increasing cost-sharing percentage over the 2017–2020 period reflects the growth in PBI's reasonably anticipated benefits relative to PPC's, driven by increasing non-Americas revenue as a proportion of total global revenue for the CSA-developed compounds.
Simmons and WVG have prepared a cost-sharing ratio analysis workbook (in Excel format) that models PPC's positions against anticipated IRS positions. The workbook includes sensitivity analyses testing the impact of various alternative RAB calculation methodologies, cost pool compositions, and revenue allocation assumptions on PBI's cost-sharing percentage. This workbook will be used to assess the potential financial impact of any IRS challenge to PPC's cost-sharing ratios.
4.2 Legacy IP Royalty Payments (PPC Position at 4.5%)
The following table summarizes the non-Americas net sales of legacy compounds and the corresponding royalty payments from PBI to PPC at the 4.5% contractual rate:
The declining trajectory of royalty payments reflects the natural product lifecycle maturation of PPC's legacy compounds, which are in the late stages of their commercial lifecycles and face increasing generic competition in non-Americas markets.
C&H has prepared and maintains a financial model comparing the royalty payments at PPC's 4.5% rate against potential IRS positions at various alternative rates (ranging from 7.0% to 11.0%). This model quantifies the potential exposure associated with each potential IRS position on the royalty rate and is used in conjunction with the WVG CUT analysis to evaluate the strength of PPC's defense.
5. Anticipated IRS Positions and Potential Exposure
Based on the pattern and content of IDR requests received to date, the information gathered during the examination, and C&H's experience in comparable transfer pricing examinations, C&H anticipates that the IRS will challenge PPC's transfer pricing positions in the following four areas:
(1) PCT Undervaluation. The IRS may assert that the $312 million PCT payment made by PBI on July 1, 2012 undervalued the pre-existing intangible property contributed by PPC to the CSA. The IRS's potential valuation of the PCT could be as high as $852 million, based on a lower WACC assumption of 7.2%. Although the 2012 PCT is outside the formal examination years (2017–2020), the IRS may seek to use an alleged PCT undervaluation as a basis for recharacterizing or adjusting the ongoing CSA arrangements and royalty payments during the examination period. The WVG PCT valuation analysis and WACC technical memorandum are specifically designed to rebut this position.
(2) CSA Cost-Sharing Ratios. The IRS is anticipated to challenge PBI's cost-sharing percentages, proposing increases of approximately 8 to 12 percentage points per year. Such adjustments would be based on the IRS's alternative RAB calculations, which may utilize different revenue allocation methodologies, cost pool compositions, or benefit projections. The WVG CPM/TNMM analysis and the cost-sharing ratio analysis workbook provide the analytical foundation for defending PPC's cost-sharing ratios.
(3) Legacy IP Royalty Rate. The IRS is anticipated to propose a royalty rate significantly above PPC's 4.5% rate, potentially as high as 11.0%, based on the IRS's own selection of purportedly comparable license agreements. The WVG CUT analysis, which demonstrates that PPC's 4.5% rate is at the median of the arm's-length range (3.1%–6.8%), is the primary defense against this challenge.
(4) PBI Economic Substance / DEMPE Functions. The IRS may argue that key DEMPE functions remained in the United States and that PBI lacked the economic substance to justify the attribution of significant residual profits to Ireland. The functional analysis, PBI personnel interview summaries, and board minutes analysis are designed to rebut this argument by demonstrating PBI's substantive operational presence and independent decision-making capacity.
Preliminary Exposure Estimate. Based on the anticipated IRS positions described above, C&H estimates that total proposed adjustments could range from approximately $300 million to $400 million across all four tax years (2017–2020). This estimate reflects the combined impact of potential adjustments to the CSA cost-sharing ratios, the legacy IP royalty rate, and any PCT-related recharacterization. At the applicable tax rates (35% for TY 2017; 21% for TY 2018–2020), the corresponding potential federal income tax exposure ranges from approximately $75 million to $110 million, before consideration of interest and any potential penalties.
It is important to emphasize that no formal IRS position has been communicated. No NOPA has been issued. The examination remains in the information-gathering phase, and the IRS's actual positions may differ from the anticipated positions described above. C&H's economic analyses and functional analysis work are designed to preemptively and comprehensively address each of these anticipated positions.
6. Document Preservation and Privilege
Document Preservation. The document preservation notice issued by C&H on June 6, 2022 to PPC, PBI, PHL, and PMI remains in full force and effect. The notice requires that all documents and electronically stored information potentially relevant to the IRS examination be preserved and protected from destruction, alteration, or loss. C&H has confirmed with PPC's legal and IT departments that the preservation hold is being maintained and that no responsive documents have been destroyed or altered since the issuance of the notice.
Privilege Protocol. The privilege protocol memorandum prepared by Leonard Cross on June 10, 2022 continues to govern all communications related to the examination, including the Kovel arrangement with WVG. The protocol establishes clear guidelines for maintaining attorney-client privilege and work-product protection over all C&H work product, all WVG analyses prepared under the Kovel arrangement, and all internal strategy communications between C&H and PPC. All PPC personnel who communicate with C&H regarding the examination have been instructed on the proper procedures for maintaining privilege.
Privilege Log. The privilege log is maintained and updated with each IDR response. The log identifies each document withheld from production on the grounds of attorney-client privilege or work-product protection, including the date of the document, the author, the recipients, and the nature of the privilege claimed. The privilege log is current through December 31, 2022.
Maintenance of Work Product. All C&H work product — including research memoranda, functional analysis documents, strategy memoranda, and correspondence — is maintained in C&H's secure document management system. All WVG analyses, workpapers, and communications are maintained under the Kovel arrangement and are subject to the same privilege protections. All internal strategy documents and communications between C&H attorneys are maintained as attorney work product.
7. Budget and Fee Status
7.1 Calderwood & Harkness Fees
C&H's original engagement letter, executed in May 2022, estimated total professional fees in the range of $4.5 million to $7.0 million through Appeals resolution, depending on the scope and duration of the examination and any subsequent administrative proceedings. The fee estimate assumed a full IDR phase, potential NOPA and protest, and representation before the IRS Office of Appeals.
C&H fees billed through Q4 2022, covering the cumulative period from engagement through December 31, 2022, total approximately $1,946,000. This figure represents approximately one-third of C&H's expected total fees of $5,837,420, which is consistent with the progress of the matter through the initial IDR phase and the substantial work completed on the functional analysis, legal research, and intercompany agreement analyses.
C&H's 2022 billing rates for the timekeepers assigned to this matter are as follows:
Fees are tracking within budget for this phase of the examination. The intensive IDR response activity and the completion of the functional analysis and legal research memoranda during Q3 and Q4 2022 represent a front-loaded investment that is expected to yield efficiencies in subsequent quarters as the examination progresses. Detailed hours by timekeeper are set forth in the accompanying Q4 2022 billing summary attached as Appendix C.
7.2 Whitmore Valuation Group Fees
WVG is engaged at a blended hourly rate of $650 per hour under the Kovel arrangement (reference 1018-00009-KV). WVG fees billed through Q4 2022 reflect a significant portion of WVG's expected total fees of $2,146,800, consistent with the completion of the CUT analysis, CPM/TNMM analysis, PCT valuation analysis, and WACC technical memorandum during Q4 2022. Approximately $1,430,000 in WVG fees have been billed through year-end 2022, reflecting the substantial economic analysis work completed during the quarter. The remaining WVG fees are expected to be incurred in connection with any supplemental analyses, engagement with IRS economist Dr. Washburne, and potential expert testimony preparation in later phases of the matter.
7.3 Thornbury & Keogh Fees
T&K's fees to date are modest, reflecting the limited scope of T&K's involvement during the initial phase of the examination. T&K's total projected engagement fees are estimated at €312,500 (approximately $341,200 at current exchange rates). These fees are expected to be incurred over the full course of the examination and any subsequent proceedings.
7.4 Total Professional Fee Projection
Projected total professional fees for the matter remain within the originally estimated range set forth in C&H's engagement letter. No unexpected costs or scope expansions were incurred during Q4 2022. The overall fee trajectory is consistent with C&H's initial projections and reflects the efficient coordination among C&H, WVG, T&K, and Crestfield. C&H will continue to monitor fees and provide updated projections as the examination progresses.
8. Key Upcoming Events and Q1 2023 Outlook
C&H anticipates the following key events and activities during Q1 2023:
Continued IDR Responses. C&H will continue responding to outstanding and forthcoming IDRs. We anticipate that the pace of IDR issuance will continue through 2023, with a total of approximately 47 IDRs ultimately being issued through September 2023. The IDR response team of Simmons and Nazari will continue to coordinate with PPC's internal tax and finance teams and with T&K and Crestfield as necessary to compile responsive documentation.
IRS Economist Engagement. C&H anticipates increasing engagement from IRS economist Dr. Washburne in Q1 2023. This engagement may take the form of informal information requests, telephone conferences, or in-person meetings. C&H and WVG (Dr. Vasquez and Dr. Chakrabarti) are prepared to engage with Dr. Washburne on all economic issues, including the CUT analysis, CPM/TNMM analysis, PCT valuation, and WACC methodology. Cross will serve as the primary C&H contact for any communications with Dr. Washburne.
Updated Functional Analysis. C&H plans to prepare an updated version of the functional analysis of PBI in early-to-mid 2023, incorporating additional employee interview data and documentary evidence gathered during the ongoing IDR process. The revised functional analysis is targeted for completion by March 15, 2023. This updated analysis will reflect any additional information obtained through IDR responses and will serve as the definitive version of the functional analysis for submission to the IRS if and when appropriate.
Potential Mid-Examination Conference. C&H anticipates that the IRS examining team may propose a mid-examination conference in Spring 2023 to discuss the progress of the examination and the IRS's preliminary views on the issues under review. Such conferences are common in large transfer pricing examinations and provide an opportunity for taxpayers to present their positions informally before the issuance of any NOPA. C&H will advise PPC on the strategic implications of such a conference and will prepare appropriate materials.
Statute of Limitations Monitoring. The statute of limitations for Tax Year 2017 requires careful attention. Under IRC § 6501(a), the general three-year statute of limitations for TY 2017 would have expired on the extended filing deadline (October 15, 2021, assuming a timely filed extension) plus three years. However, because transfer pricing adjustments may implicate the six-year statute under IRC § 6501(e)(1)(C) for substantial omissions attributable to foreign financial asset reporting, and because the IRS may assert the application of the unlimited statute under certain circumstances, C&H is monitoring the statute closely. If necessary, C&H will prepare Form 872 (Consent to Extend the Time to Assess Tax) for PPC's execution and submission to the IRS.
Hargrove National Bank Credit Facility. C&H is monitoring PPC's $1.5 billion revolving credit facility with Hargrove National Bank (Administrative Agent: Christine Bellucci) for any material-tax-event triggers. Under the credit facility's tax covenants, PPC is required to report certain material tax events to the Administrative Agent. Based on the current status of the examination — no NOPA issued, no formal IRS position communicated, and the examination remaining in the information-gathering phase — no reporting obligation has been triggered to date. C&H will continue to monitor this obligation and advise PPC promptly if any reporting trigger is reached.
SEC Disclosure Considerations. C&H is monitoring PPC's SEC disclosure obligations regarding the examination in connection with PPC's 10-K and 10-Q filings. Under ASC 450-20 (contingencies) and ASC 740-10 (income taxes), PPC is required to disclose contingent liabilities that are probable and reasonably estimable, or that are reasonably possible and for which the potential magnitude is material. Given the early phase of the examination and the absence of any NOPA or formal IRS position, no contingent liability disclosure is required at this stage. The FIN 48 / ASC 740-10 reserve of $62.4 million provides adequate disclosure of PPC's uncertain tax position related to the Irish IP structure. C&H will continue to advise PPC on disclosure obligations as the examination progresses.
Ridgeview Capital Management. Ridgeview Capital Management, an 8.3% institutional shareholder of PPC (Managing Partner Douglas Everett), has not been in direct communication with C&H regarding the examination. PPC's existing FIN 48 / ASC 740-10 reserve disclosures at $62.4 million are adequate to address any investor inquiries regarding PPC's uncertain tax positions. No additional disclosures are recommended at this time.
2023 Billing Rate Schedule. Updated C&H billing rates, effective January 1, 2023, will be circulated to PPC in the coming weeks.
9. Action Items
The following action items are identified for Q1 2023:
10. Conclusion
The IRS transfer pricing examination of PPC for Tax Years 2017–2020 continues to proceed as anticipated. Substantial progress was achieved during Q4 2022 across all major defense workstreams, including the completion of the functional analysis, the delivery of key economic analyses by WVG, and the continued timely response to IRS IDRs. PPC's transfer pricing positions remain well-supported, and C&H's defense strategy is on track.
We look forward to discussing this report with the PPC team at your earliest convenience and to scheduling the Q1 2023 strategy call referenced above. Please do not hesitate to contact Leonard Cross or Sylvia Hartwell with any questions.
CALDERWOOD & HARKNESS LLP
By: ________
Leonard Cross, Partner 1735 Market Street, Suite 3100 Philadelphia, PA 19103 Telephone: (215) 555-4200
Email: lcross@calderwoodharkness.com
Date: ________
By: ________
Sylvia Hartwell, Partner 600 Lexington Avenue New York, NY 10022 Telephone: (212) 555-7800
Email: shartwell@calderwoodharkness.com
Date: ________
Appendices (Referenced — Distributed Separately)
The following appendices are referenced in this Matter Status Report and are distributed separately as privileged and confidential attachments:
Appendix A: IDR Tracker — Master Log (current through December 31, 2022). This appendix contains the complete IDR tracking log, including the IDR number, date received, subject matter, response deadline, actual response date, documents produced (with Bates number references), and current status of each IDR.
Appendix B: Key Events Timeline (May 2022 – December 2022). This appendix provides a chronological timeline of all significant events in the examination from the opening of the examination on May 16, 2022 through December 31, 2022, including IDR issuances and responses, delivery of economic analyses, completion of key work product, and communications with the IRS examining team.
Appendix C: Q4 2022 Billing Summary. This appendix contains the detailed billing summary for Q4 2022, including hours and fees by timekeeper for C&H, WVG fees under the Kovel arrangement, and T&K fees. Cumulative year-to-date and engagement-to-date totals are included.
Appendix D: Statute of Limitations Status. This appendix provides a summary of the statute of limitations for each of the four tax years at issue (2017–2020), including the original filing dates, extended filing dates, applicable statute periods, and current expiration dates. The appendix identifies any statute periods requiring attention and any Form 872 consents that may need to be prepared.
PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT COMMUNICATION ATTORNEY WORK PRODUCT — PREPARED IN ANTICIPATION OF LITIGATION CALDERWOOD & HARKNESS LLP — MATTER NO. 1018-00009 © 2023 Calderwood & Harkness LLP. All rights reserved.
| Role | Name | Status / Notes | |
| Supervisory Revenue Agent (Team Manager) | Gerald Meskill | Overall supervisory authority over the examination | |
| Lead Revenue Agent | Patricia Dunleavy | Primary point of contact for IDRs and day-to-day examination communications | |
| IRS Economist (IRS Transfer Pricing Practice) | Dr. Alan Washburne | Identified as assigned to the case; has not yet engaged directly with C&H during Q4 2022 | |
| IRS Office of Chief Counsel Attorney-Advisor | Franklin Rosario | No direct engagement to date | |
| Product | Global Net Sales (2020) | Non-Americas Net Sales (2020) | |
| Veritaxol | $3.12 billion | $1.34 billion | |
| Imvara | $1.87 billion | $0.79 billion | |
| Cerulon | $0.62 billion | $0.28 billion | |
| Tax Year | Qualified R&D Cost Pool | ||
| 2017 | $487.3 million | ||
| 2018 | $523.8 million | ||
| 2019 | $561.2 million | ||
| 2020 | $598.4 million | ||
| Tax Year | PBI Cost-Sharing % | Total R&D Cost Pool | PBI Share ($ Amount) |
| 2017 | 38.2% | $487.3 million | $186.15 million |
| 2018 | 39.6% | $523.8 million | $207.42 million |
| 2019 | 41.1% | $561.2 million | $230.65 million |
| 2020 | 42.7% | $598.4 million | $255.52 million |
| Tax Year | Non-Americas Net Sales (Legacy Compounds) | Royalty Rate | Royalty Payment |
| 2017 | $814.6 million | 4.5% | $36.66 million |
| 2018 | $762.3 million | 4.5% | $34.30 million |
| 2019 | $691.8 million | 4.5% | $31.13 million |
| 2020 | $624.1 million | 4.5% | $28.08 million |
| Timekeeper | Title | 2022 Hourly Rate |
| Leonard Cross | Partner (Responsible) | $1,475 | |
| Sylvia Hartwell | Partner (Billing) | $1,350 | |
| Garrett Simmons | Lead Associate | $885 | |
| Leila Nazari | Working Associate | $695 | |
| No. | Action Item | Responsible | Target Date |
| 1 | Continue IDR responses per established workflow and deadlines | C&H (Simmons / Nazari) | Ongoing |
| 2 | Follow up with Crestfield (Susan Lam) on remaining R&D cost pool data and supporting documentation | Simmons | January 2023 |
| 3 | Continue Irish coordination with T&K; obtain Glenmore Bank Ireland plc records for anticipated IDR response on PBI treasury operations | Nazari | February 2023 |
| 4 | Schedule Q1 2023 strategy call with Marcus Whitfield and Deborah Staines to discuss examination status and defense strategy | Cross / Hartwell | January 2023 |
| 5 | Coordinate with Dr. Vasquez (WVG) on preparation for potential engagement with IRS economist Dr. Washburne | Simmons | January – March 2023 |
| 6 | Prepare statute of limitations tracking memo for TY 2017 and draft Form 872 consent if needed | Nazari | January – February 2023 |
| 7 | Circulate 2023 billing rate schedule to PPC | Hartwell | January 2023 |